The upcoming session, led by ARC Regulatory experts Dr. Ciara Devlin and Andrew Mercier, focuses on the company’s Sponsor Delegation service. This model functions as an extension of a sponsor's internal team, utilizing specialists to manage day-to-day governance, vendor relations, and site coordination. By embedding clinical and regulatory expertise directly into the study lifecycle, organizations can maintain oversight while offloading the administrative burden that often complicates diagnostic research.

A core theme of the discussion is the shift toward agile, risk-based monitoring strategies. Rather than relying on rigid oversight, the hybrid approach combines centralized data monitoring with targeted on-site visits. This framework aims to improve proactive risk identification and stakeholder communication, ensuring that challenges are addressed before they impact study timelines or data integrity. For companies with limited internal resources, the presentation will offer a blueprint for scaling study management while keeping a clear focus on product innovation.